Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for bone metastasis prevention in prostate cancer
NCT00286091Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2006
- Primary completion
- Jul 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of denosumab in prostate cancer (PCa), sponsored by Amgen. Started Jan 2006; status: completed.
02
Drugs
denosumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00286091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286091.